Press Release: Osimertinib Efficacy Against Intracranial EGFRvIII-Positive GBMs

The Glioblastoma Drug Discovery Group announces that osimertinib significantly prolongs the survival of immunocompromised mice bearing intracranial EGFRvIII-positive glioblastoma! These data warrant the commencement of studies designed to test osimertinib’s safety and efficacy in GBM patients.


This entry was posted on Wednesday, November 23rd, 2016 at 4:40 pm and is filed under Uncategorized. You can follow any responses to this entry through the RSS 2.0 feed. You can leave a response, or trackback from your own site.

Leave a Reply

Your email address will not be published. Required fields are marked *